


*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



INSILICO MEDICINE

**InSilico Medicine Cayman TopCo**

**英矽智能**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 3696)**

**VOLUNTARY ANNOUNCEMENT  
INITIATION OF INSILICO MEDICINE'S RENTOSERTIB  
PHASE III CLINICAL TRIAL**

This announcement is made by InSilico Medicine Cayman TopCo (the “**Company**”, together with its subsidiaries, the “**Group**” or “**Insilico Medicine**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that Rentosertib (ISM001-055), independently discovered and developed by Insilico Medicine, has officially entered Phase III clinical trial (CTR20262475, NCT07687459), and relevant information has been publicly disclosed on the official registration platform of the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA), and registered on the ClinicalTrials.gov website.

The prospective, randomized, double-blind, placebo-controlled, parallel-group Phase III study is designed to evaluate the efficacy and safety of Rentosertib administered once daily for 52 weeks, and is expected to enroll a total of 320 participants across 47 centers in China.

The study includes an investigational treatment arm and a control arm, with participants randomized to receive either Rentosertib tablets or placebo tablets. The primary endpoint is the annual rate of decline in forced vital capacity (FVC) over 52 weeks. Secondary endpoints include time to first disease progression, change in diffusing capacity of the lungs for carbon monoxide (DLCO), and questionnaire-based quality-of-life assessments.

**About Rentosertib (ISM001-055)**

Rentosertib (ISM001-055) is a potentially first-in-class small-molecule TNIK inhibitor, discovered and developed with the support of Insilico Medicine’s proprietary generative AI platform, Pharma.AI. The Food and Drug Administration of the U.S. (FDA) granted Orphan Drug Designation (ODD) to Rentosertib for the treatment of idiopathic pulmonary fibrosis (the “**IPF**”) in February 2023. The CDE announced the inclusion of Rentosertib in the list of Breakthrough Therapy Designation (BTD) for the treatment of IPF in May 2025.

## **Forward Looking Statement**

There is no assurance that any forward-looking statements regarding the business development of the Group in this announcement or any of the matters set out herein are attainable, will actually occur or will be realized or are complete or accurate. The financial and other data relating to the Group as disclosed in this announcement has also not been audited or reviewed by its auditors. Shareholders and/or potential investors of the Company are advised to exercise caution when dealing in the shares of the Company and not to place any excessive reliance on the information disclosed herein. Any shareholder or potential investor who is in doubt is advised to seek advice from professional advisors.

By order of the Board  
**InSilico Medicine Cayman TopCo**  
**Mr. Aleksandrs Zavoronkovs, Ph.D.**  
*Chairman, Executive Director, CEO and CBO*

Hong Kong, July 8, 2026

*As at the date of this announcement, the Board comprises Mr. Aleksandrs Zavoronkovs, Ph.D. and Mr. Feng Ren, Ph.D. as executive directors; Mr. Kan Chen, Ph.D., Mr. Chuen Yan Leung, Ph.D., and Mr. Long Shi as non-executive directors; and Mr. Jingsong Wang, Ph.D., Ms. Denitsa Milanova, Ph.D. and Mr. Roman Kyrychynskyi as independent non-executive directors.*